sorafenib has been researched along with cardiovascular agents in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cardiovascular agents) | Trials (cardiovascular agents) | Recent Studies (post-2010) (cardiovascular agents) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 17,645 | 1,480 | 6,891 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arain, S; Balanescu, DV; Donisan, T; Gould, KL; Hassan, S; Iliescu, C; Karimzad, K; Kim, P; Lopez-Mattei, J; Palaskas, N; Sudasena, D | 1 |
| Huang, C; Zhang, W; Zhu, Y | 1 |
2 other study(ies) available for sorafenib and cardiovascular agents
| Article | Year |
|---|---|
Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib.
Topics: Adult; Antineoplastic Agents; Cardiotoxicity; Cardiovascular Agents; Coronary Artery Disease; Coronary Restenosis; Defibrillators; Defibrillators, Implantable; Drug-Eluting Stents; Electric Countershock; Endovascular Procedures; Humans; Intra-Aortic Balloon Pumping; Leukemia, Myeloid, Acute; Male; Myocardial Infarction; Peripheral Arterial Disease; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2019 |
Drug-eluting stent specifically designed to target vascular smooth muscle cell phenotypic modulation attenuated restenosis through the YAP pathway.
Topics: Animals; Aorta; Apoptosis Regulatory Proteins; Cardiovascular Agents; Carotid Arteries; Carotid Stenosis; Cell Proliferation; Cells, Cultured; Drug-Eluting Stents; Male; Models, Animal; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nuclear Proteins; Phenotype; Prosthesis Design; Prosthesis Implantation; Rabbits; Rats; Serum Response Factor; Signal Transduction; Sorafenib; Trans-Activators; YAP-Signaling Proteins | 2019 |